CRBU
Caribou Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.56
−0.64%Year over year
Reported trailing growth
- Revenue
- +10.0%
- EBITDA
- +29.3%
- EBIT
- +34.7%
- EPS
- +39.3%
- Free cash flow
- +29.5%
- Operating cash flow
- +28.0%
Forward estimates
Based on analyst estimates
- Revenue
- +113.1%
- EBITDA
- +53.3%
- EPS
- +53.9%
Three-year CAGR
- Revenue
- -7.0%
- EBITDA
- +0.1%
- EBIT
- +18.3%
- Net income
- +0.7%
- EPS
- +3.6%
- Free cash flow
- +22.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026